Previous 10 | Next 10 |
2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...
Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference PR Newswire REDWOOD CITY, Calif. , April 13, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development o...
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights PR Newswire -- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-te...
Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference PR Newswire REDWOOD CITY, Calif. , Feb. 21, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovativ...
H.C. Wainwright has initiated Arcellx ( NASDAQ: ACLX ) with a buy saying that the company's CAR-T therapies in development have advantages over marketed ones and its partnership with Gilead Sciences' ( GILD ) Kite Therapeutics will reap benefits. The firm has a $42 price target (~...
Arcellx to Participate in Upcoming Investor Conferences PR Newswire REDWOOD CITY, Calif. , Feb. 2, 2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patien...
Gilead Sciences' ( NASDAQ: GILD ) Kite unit and Arcellx ( NASDAQ: ACLX ) have finalized a collaboration for the further development of CART-ddBCMA, the latter company's lead treatment for relapsed or refractory multiple myeloma. The T-cell therapy, currently in phase 2, will b...
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatme...
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
Summary Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead. Arcellx goes up against Johnson & Johnson's formidable carvykti, but now it has help. Arcellx, Inc. ( ACLX ) is up 83% since my bullish coverage f...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 14:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 12:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...